宗成利 博士 教授 博士生導師

  課題組網頁：http://zong.scigoogle.com/

  聯系方式：海南省海口市人民大道58号365英国上市官网在线藥學系，570228

  郵箱：chengli.zong@hainanu.edu.cn

  1.教育及工作背景

  2020.10-至今  365英国上市官网在线 教授

  2016.08-2020.10 默沙東制藥公司-美國費城 高級科學家  

  2010.09-2016.05喬治亞大學（university of Georgia）-複雜碳水化合物研究中心（Complex Carbohydrate Research Center）（博士）

  2007.09-2010.07中國海洋大學-365英国上市官网在线（碩士）

  2003.09-2007.07中國海洋大學-365英国上市官网在线（本科）

2.科研情況

細菌疫苗新策略，新型腫瘤疫苗，疫苗佐劑活性增強研究

365英国上市官网在线-邁科康生物科技有限公司“先進疫苗研究聯合實驗室”-負責人

海南大學-糖類小分子藥物及多糖疫苗研究創新團隊-負責人

3.研究領域

多糖疫苗，免疫學，藥物化學，糖化學生物學

4.代表性項目

（1）腫瘤疫苗

新型原位腫瘤疫苗，基于腫瘤表面特殊抗原的亞單位疫苗。

（2）針對超級耐藥菌的多糖疫苗研究

作為肺炎球菌多糖領域的行業專家，參與了默沙東下一代肺炎球菌疫苗的開發：例如細菌的發酵，莢膜多糖的分離，純化，活化，與CRM197偶聯等。參與研究的默沙東多價肺炎球菌結合型疫苗研發V114和V116項目已經進入臨床實驗。

（3）糖胺聚糖的化學生物學研究

建立了一種可以快速合成糖胺聚糖類化合物的保護基以及純化策略，為此類化合物的構效關系研究奠定了基礎。領導并完成了以下項目：建立了一個硫酸肝素四糖化合物庫，通過微陣列篩選，發現了一系列硫酸肝素結合蛋白的底物特點；發現了一個在神經導向過程中起重要作用的硫酸肝素八糖結構；發現了一種可以修飾哺乳動物細胞表面的新方法；确定了腫瘤細胞表面一種特殊的硫酸軟骨素A。

5.代表性成果

1）Ma, W.^#; Xu, Z.^#; Teng, C.^#; Cao, C.; Wu, R.; Meng, X.; Sui, Q.; Gao, Q.^*; Zong, C.^*; Li, T.^*, Enhanced Antitumor Immunity of a Globo H‐Based Vaccine Enabled by the Combination Adjuvants of 3D‐MPL and QS‐21. Angewandte Chemie International Edition, 2025, 64, e202418948. IF=16.1 一區

2）Teng, C.^#, Ma, W.^#, Liu, J.^#, Hou, J., Zhang, Y., Meng, X., Xue, Y., Wang, Z., Wang, J., Chen, D., Sui, Q., Gao, Q., Li, X.^*, Li, T.^*, & Zong, C.^*, Chemoenzymatic liquid-phase synthesis and immunogenic assessment of tumor-associated complex MUC1 glycopeptide variants. International Journal of Biological Macromolecules, 2025, 302, 140525. IF=7.7 一區

3）Xu, Y. ^#; Yang, J.; Meng, X. ^#; Meng, S.; Sun, T. ^*; Ding, N. ^*; Zong, C. ^*, The synthesis and preliminary immunological evaluation of a dual-adjuvant SARS-CoV-2 RBD vaccine: Covalent integration of TLR7/8 and iNKT cell agonists. International Journal of Biological Macromolecules, 2024, 270, 132258. IF=8.2 一區

4）Meng, X. ^#, Xu, Y. ^#, Yang, J., Meng, S., Ding, N., Sun, T.; Zong, C. ^*, Strategic development of a self-adjuvanting SARS-CoV-2 RBD vaccine: From adjuvant screening to enhanced immunogenicity with a modified TLR7 agonist. International Immunopharmacology, 2024, 132, 111909. IF=5.6 二區

5）Yang, J. ^#; Meng, X.; Rao, Y.; Wang, X.; Meng, S.; Teng, C.; Sun, T. ^*; Zong, C.^*, Harnessing the potential of de-sulfated heparin for targeted drug delivery: A three-component approach exemplified by conjugation with galactose and paclitaxel. Carbohydrate Polymers, 2024, 333, 121986. IF=11.2 一區

6）Weng, W. ^#; Ren, S. ^#; Teng, C. ^#; Guo, J.; Guo, Q.; Zhang, W.; Zong, C.^*; Ding, N.*, Chemoenzymatic Synthesis and Immunological Evaluation of sialyl-Thomsen-Friedenreich (sTF) Antigen Conjugate to CRM197. 2024, Bioorganic & Medicinal Chemistry, 117615. IF=3.5 三區

7）Shen, Y. ^#; Yuan, H. ^#; Guo, Z.; Li, X.; Yang, Z.^*; Zong, C.^*, Exonuclease III Can Efficiently Cleave Linear Single-Stranded DNA: Reshaping Its Experimental Applications in Biosensors. Biosensors, 2023, 13, 581. IF=5.5 二區

8）Teng, C. ^#; Meng, X.; Hu, Y.; Mao, H.; Li, H.; Yang, J.; Sun, T.; Meng, S.; Zong, C.^*, Self-assembled TLR7/8 agonist-mannose conjugate as an effective vaccine adjuvant for SARS-CoV-2 RBD trimer. Polymers, 2022, 14, 5466. IF=5.0 二區

9）Sun, T. ^#; Mai, S-Y. ^#; Mao, H-Z.; Li, H-T.; Duan, Y-Y.; Meng, S.; Bao, J-L.; Ding, N.; Zong, C.^*, Conjugate of Structurally Reassigned Pneumococcal Serotype 31 Polysaccharide with CRM197 Elicited Potent Immune Response. Carbohydrate Polymers, 2022, 289, 119414 IF=11.2 一區

10）Li, H.^#; Chen, C.; Mao, H-Z.; Xu, Y.; Meng, S.; Sun, T-T.; Zong, C.^*, Efficient synthesis of α-galactosylceramide and its C-6 modified analogues, Frontiers in Chemistry, 2022, 10, 1039731 IF=5.5 三區

11）Wan, Y. ^#; Zong, C.^#; Li, X-P.; Wang, A.; Li, Y.; Yang, T.; Bao, Q.; Dubow, M.; Yang, M.^*; Rodrigo, L-A. ^*; Mao, C. ^*, New Insights for Biosensing: Lessons from Microbial Defense System. Chemical Reviews, 2022, 122, 8126-8180 綜述 IF=62.1 一區

12）Zong, C.^#; Fang, L.; Song, F.; Wang, A.; Wan, Y.^*, Fluorescent Fingerprint Bacteria by Multi-channel Magnetic Fluorescent Nanosensor. Sensors and Actuators B: Chemical. 2019, 289, 234-241. IF=8.4 一區

13）Zong, C.^#; Venot, A., Li, X.; Lu, W; Xiao, W.; Wilkes, J-W; Salanga, C-L.; Handel, T-M.; Wang, L.; Wolfert, M-A.; Boons, G-J.^*, Heparan Sulfate Microarray Reveals that Heparan Sulfate-Protein Binding Exhibit Different Ligand Requirements. Journal of the American Chemical Society, 2017, 139, 9534-9543. IF=15.0一區

14）Zong, C.^#; Huang, R.; Condac, E.; Chiu, Y.; Xiao, W.; Li, X.; Lu, W.; Ishihara, M.; Wang, S.; Ramiah, A.; Stickney, M.; Azadi, P.; Amster, I-J.; Moremen, K-W.; Wang, L.; Sharp, J-S.; Boons, G-J.^*, Integrated Approach to Identify Heparan Sulfate Ligand Requirements of Robo1. Journal of the American Chemical Society, 2016, 138, 13059-13067. IF=15.0 一區

15）Zong, C.^#; Venot, A.; Dhamale, O-P.; Boons, G-J.^*, Fluorous supported modular synthesis of heparan sulfate oligosaccharides. Org. Lett., 2013, 15, 342–345. IF=5.2一區

16）Zong, C. ^#; Li, Z.; Sun, T.; Wang, P.; Li, Y.^*, “Convenient Synthesis of Sulfated Oligofucosides” Carbohydr. Res. 2010. 11, 1522-1532. IF=3.1 三區

17）Lu, W.^#; Zong, C.; Chopra, P.; Pepi, L.; Xu, Y.; Amster, J.; Liu, J.; Boons, G-J.^*, Controlled chemoenzymatic synthesis of heparan sulfate oligosaccharide. Angewandte Chemie, 2018, 57, 5340-5344. IF=16.6 一區

18）Capicciotti, C. J. ^#; Zong, C.; Sheikh, M.; Sun, T.; Wells, L.; Boons, G-J.^*, Cell-Surface Glyco-Engineering by Exogenous Enzymatic Transfer using a Bi-Functional CMP-Neu5Ac Derivative. Journal of the American Chemical Society, 2017, 139, 13342-13348. IF=15.0 一區

19）Huang, R.^#; Zong, C.; Venot, A.; Chiu, Y.; Zhou, D.; Boons G-J.; Sharp, J.^*, The de novo Sequencing of Complex Mixtures of Heparan Sulfate Oligosaccharides. Analytical Chemistry, 2016, 88, 5299-5307. IF=7.4 一區